AAAAAA

   
Results: 1-15 |
Results: 15
OUTCOME OF COMBINATION CHEMOTHERAPY IN EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER - ANY TREATMENT RELATED PROGRESS
Authors: LASSEN UN HIRSCH FR OSTERLIND K BERGMAN B DOMBERNOWSKY P
Citation: Un. Lassen et al., OUTCOME OF COMBINATION CHEMOTHERAPY IN EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER - ANY TREATMENT RELATED PROGRESS, Lung cancer, 20(3), 1998, pp. 151-160
CANCER REVIEWS NEED TO BE SYSTEMATIC - BUT HOW
Authors: OSTERLIND K
Citation: K. Osterlind, CANCER REVIEWS NEED TO BE SYSTEMATIC - BUT HOW, Lung cancer, 19(2), 1998, pp. 99-100
P53 PROTEIN IN NON-SMALL-CELL LUNG-CANCER AS QUANTITATED BY ENZYME-LINKED-IMMUNOSORBENT-ASSAY - RELATION TO PROGNOSIS
Authors: PAPPOT H FRANCIS D BRUNNER N GRONDAHLHANSEN J OSTERLIND K
Citation: H. Pappot et al., P53 PROTEIN IN NON-SMALL-CELL LUNG-CANCER AS QUANTITATED BY ENZYME-LINKED-IMMUNOSORBENT-ASSAY - RELATION TO PROGNOSIS, Clinical cancer research, 2(1), 1996, pp. 155-160
SUPERIORITY OF CISPLATIN OR CARBOPLATIN IN COMBINATION WITH TENIPOSIDE AND VINCRISTINE IN THE INDUCTION CHEMOTHERAPY OF SMALL-CELL LUNG-CANCER - A RANDOMIZED TRIAL WITH 5 YEARS FOLLOW-UP
Authors: LASSEN U KRISTJANSEN PEG OSTERLIND K BERGMAN B SIGSGAARD TC HIRSCH FR HANSEN M DOMBERNOWSKY P HANSEN HH
Citation: U. Lassen et al., SUPERIORITY OF CISPLATIN OR CARBOPLATIN IN COMBINATION WITH TENIPOSIDE AND VINCRISTINE IN THE INDUCTION CHEMOTHERAPY OF SMALL-CELL LUNG-CANCER - A RANDOMIZED TRIAL WITH 5 YEARS FOLLOW-UP, Annals of oncology, 7(4), 1996, pp. 365-371
TUMOR-MARKER AIDED DISCRIMINATION BETWEEN DISEASE STAGES IN SMALL-CELL LUNG-CANCER (SCLC)
Authors: JORGENSEN LGM OSTERLIND K GOMM SA HERNANDEZ JR JOHNSON PWM LOBER J SPLINTER TAW SZTURMOWICZ M
Citation: Lgm. Jorgensen et al., TUMOR-MARKER AIDED DISCRIMINATION BETWEEN DISEASE STAGES IN SMALL-CELL LUNG-CANCER (SCLC), Journal of tumor marker oncology, 11(4), 1996, pp. 7-14
SERUM NEURON-SPECIFIC ENOLASE (S-NSE) AND THE PROGNOSIS IN SMALL-CELLLUNG-CANCER (SCLC) - A COMBINED MULTIVARIABLE ANALYSIS ON DATA FROM 9CENTERS
Authors: JORGENSEN LGM OSTERLIND K GENOLLA J GOMM SA HERNANDEZ JR JOHNSON PWM LOBER J SPLINTER TAW SZTURMOWICZ M
Citation: Lgm. Jorgensen et al., SERUM NEURON-SPECIFIC ENOLASE (S-NSE) AND THE PROGNOSIS IN SMALL-CELLLUNG-CANCER (SCLC) - A COMBINED MULTIVARIABLE ANALYSIS ON DATA FROM 9CENTERS, British Journal of Cancer, 74(3), 1996, pp. 463-467
SERUM NEURON-SPECIFIC ENOLASE (S-NSE) AND THE PROGNOSIS IN SMALL-CELLLUNG-CANCER (SCLC) - A COMBINED MULTIVARIABLE ANALYSIS ON DATA FROM 9CENTERS (VOL 74, PG 463, 1996)
Authors: JORGENSEN LGM OSTERLIND K GENOLLA J GOM SA HERNANDEZ JR JOHNSON PWM LOBER J SPLINTER TAW SZTURMOWICZ M
Citation: Lgm. Jorgensen et al., SERUM NEURON-SPECIFIC ENOLASE (S-NSE) AND THE PROGNOSIS IN SMALL-CELLLUNG-CANCER (SCLC) - A COMBINED MULTIVARIABLE ANALYSIS ON DATA FROM 9CENTERS (VOL 74, PG 463, 1996), British Journal of Cancer, 74(12), 1996, pp. 2043-2043
LONG-TERM SURVIVAL IN SMALL-CELL LUNG-CANCER - POSTTREATMENT CHARACTERISTICS IN PATIENTS SURVIVING 5 TO 18- AN ANALYSIS OF 1,714 CONSECUTIVE PATIENTS( YEARS )
Authors: LASSEN U OSTERLIND K HANSEN M DOMBERNOWSKY P BERGMAN B HANSEN HH
Citation: U. Lassen et al., LONG-TERM SURVIVAL IN SMALL-CELL LUNG-CANCER - POSTTREATMENT CHARACTERISTICS IN PATIENTS SURVIVING 5 TO 18- AN ANALYSIS OF 1,714 CONSECUTIVE PATIENTS( YEARS ), Journal of clinical oncology, 13(5), 1995, pp. 1215-1220
EFFECT OF THORACIC RADIOTHERAPY ON MORTALITY IN LIMITED SMALL-CELL LUNG-CANCER - A METAANALYSIS OF 13 RANDOMIZED TRIALS AMONG 2,140 PATIENTS
Authors: ARRIAGADA R PIGNON JP IHDE DC JOHNSON DH PERRY MC SOUHAMI RL BRODIN O JOSS RA KIES MS LEBEAU B ONOSHI T OSTERLIND K TATTERSALL MHN WAGNER H
Citation: R. Arriagada et al., EFFECT OF THORACIC RADIOTHERAPY ON MORTALITY IN LIMITED SMALL-CELL LUNG-CANCER - A METAANALYSIS OF 13 RANDOMIZED TRIALS AMONG 2,140 PATIENTS, Anticancer research, 14(1B), 1994, pp. 333-335
TREATMENT EVALUATION
Authors: HANSEN H PERRY M ARRIAGADA R CHASTANG C DRINGS P OSTERLIND K PARMAR M PIGNON JP THATCHER N
Citation: H. Hansen et al., TREATMENT EVALUATION, Lung cancer, 10, 1994, pp. 190000007-190000009
FACTORS CONFOUNDING EVALUATION OF TREATMENT EFFECT IN LUNG-CANCER
Authors: OSTERLIND K
Citation: K. Osterlind, FACTORS CONFOUNDING EVALUATION OF TREATMENT EFFECT IN LUNG-CANCER, Lung cancer, 10, 1994, pp. 190000097-190000103
PROGNOSTIC IMPACT OF UROKINASE, UROKINASE RECEPTOR, AND TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR IN SQUAMOUS AND LARGE-CELL LUNG-CANCER TISSUE
Authors: PEDERSEN H BRUNNER N FRANCIS D OSTERLIND K RONNE E HANSEN HH DANO K GRONDAHLHANSEN J
Citation: H. Pedersen et al., PROGNOSTIC IMPACT OF UROKINASE, UROKINASE RECEPTOR, AND TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR IN SQUAMOUS AND LARGE-CELL LUNG-CANCER TISSUE, Cancer research, 54(17), 1994, pp. 4671-4675
UROKINASE AND PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN PULMONARY ADENOCARCINOMA
Authors: PEDERSEN H GRONDAHLHANSEN J FRANCIS D OSTERLIND K HANSEN HH DANO K BRUNNER N
Citation: H. Pedersen et al., UROKINASE AND PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN PULMONARY ADENOCARCINOMA, Cancer research, 54(1), 1994, pp. 120-123
SERUM NEURON-SPECIFIC ENOLASE (S-NSE) IN PROGRESSIVE SMALL-CELL LUNG-CANCER (SCLC)
Authors: JORGENSEN LGM OSTERLIND K HANSEN HH COOPER EH
Citation: Lgm. Jorgensen et al., SERUM NEURON-SPECIFIC ENOLASE (S-NSE) IN PROGRESSIVE SMALL-CELL LUNG-CANCER (SCLC), British Journal of Cancer, 70(4), 1994, pp. 759-761
THERAPY-RELATED MYELODYSPLASIA AND ACUTE MYELOID-LEUKEMIA - CYTOGENETIC CHARACTERISTICS OF 115 CONSECUTIVE CASES AND RISK IN 7 COHORTS OF PATIENTS TREATED INTENSIVELY FOR MALIGNANT DISEASES IN THE COPENHAGEN SERIES
Authors: PEDERSENBJERGAARD J PHILIP P LARSEN SO ANDERSSON M DAUGAARD G ERSBOLL J HANSEN SW HOUJENSEN K NIELSEN D SIGSGAARD TC SPECHT L OSTERLIND K
Citation: J. Pedersenbjergaard et al., THERAPY-RELATED MYELODYSPLASIA AND ACUTE MYELOID-LEUKEMIA - CYTOGENETIC CHARACTERISTICS OF 115 CONSECUTIVE CASES AND RISK IN 7 COHORTS OF PATIENTS TREATED INTENSIVELY FOR MALIGNANT DISEASES IN THE COPENHAGEN SERIES, Leukemia, 7(12), 1993, pp. 1975-1986
Risultati: 1-15 |